NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Price Target & More

$18.86 -0.68 (-3.48 %)

(As of 04/20/2018 08:48 AM ET)

Previous Close$19.54

Today's Range$18.62 - $19.48

52-Week Range$5.47 - $23.50

Volume784,900 shs

Average Volume1.46 million shs

Market Capitalization$2.01 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.98

About Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast and lung cancer; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:SPPI

CUSIP84763A10

Webwww.sppirx.com

Phone702-835-6300

Debt

Debt-to-Equity RatioN/A

Current Ratio2.53%

Quick Ratio2.48%

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$128.37 million

Price / Sales15.09

Cash FlowN/A

Price / CashN/A

Book Value$3.49 per share

Price / Book5.40

Profitability

EPS (Most Recent Fiscal Year)($1.07)

Net Income$-91,240,000.00

Net Margins-70.66%

Return on Equity-30.68%

Return on Assets-18.40%

Miscellaneous

Employees215

Outstanding Shares102,710,000

How to Become a New Pot Stock Millionaire

Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals (NASDAQ:SPPI) released its quarterly earnings data on Tuesday, March, 6th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.04. The biotechnology company earned $28.57 million during the quarter, compared to analyst estimates of $33.18 million. Spectrum Pharmaceuticals had a negative return on equity of 30.68% and a negative net margin of 70.66%. The firm's revenue was down 18.9% on a year-over-year basis. During the same period last year, the business earned ($0.10) EPS. View Spectrum Pharmaceuticals' Earnings History.

What price target have analysts set for SPPI?

4 brokerages have issued twelve-month price objectives for Spectrum Pharmaceuticals' shares. Their forecasts range from $25.00 to $33.00. On average, they expect Spectrum Pharmaceuticals' stock price to reach $29.00 in the next twelve months. View Analyst Ratings for Spectrum Pharmaceuticals.

Who are some of Spectrum Pharmaceuticals' key competitors?

Some companies that are related to Spectrum Pharmaceuticals include FibroGen (FGEN), Blueprint Medicines (BPMC), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Advanced Accelerator Application (AAAP), Array Biopharma (ARRY), Tesaro (TSRO), Clovis Oncology (CLVS), Amicus Therapeutics (FOLD), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Evotec A.G. (EVTCY), Acadia Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Puma Biotechnology (PBYI) and Akorn (AKRX).

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:

Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 60)
Mr. Kurt A. Gustafson, Exec. VP, CFO & Principal Accounting Officer (Age 50)
Mr. Thomas J. Riga, Chief Operating Officer
Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
Mr. Keith McGahan, Sr. VP & Chief Legal Officer

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

Media stories about SPPI stock have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 0.09 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 45.89 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include SHROTRIYA RAJESH C MD (5.92%). Company insiders that own Spectrum Pharmaceuticals stock include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $18.86.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $2.01 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]

MarketBeat Community Rating for Spectrum Pharmaceuticals (SPPI)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		280 (Vote Outperform)
Underperform Votes:		193 (Vote Underperform)
Total Votes:		473

MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Spectrum Pharmaceuticals (NASDAQ:SPPI) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

4 Wall Street analysts have issued ratings and price targets for Spectrum Pharmaceuticals in the last 12 months. Their average twelve-month price target is $29.00, suggesting that the stock has a possible upside of 53.76%. The high price target for SPPI is $33.00 and the low price target for SPPI is $25.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$29.00	$29.00	$24.60	$21.6667
Price Target Upside:	53.76% upside	31.82% upside	29.20% upside	16.42% upside

Spectrum Pharmaceuticals (NASDAQ:SPPI) Consensus Price Target History

Price Target History for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ:SPPI) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/5/2018	HC Wainwright	Boost Price Target	Positive -> Buy	$33.00	High
12/18/2017	B. Riley	Initiated Coverage	Buy -> Buy	$26.00	High
10/23/2017	Guggenheim	Initiated Coverage	Buy	$32.00	N/A
10/20/2017	Jefferies Group	Boost Price Target	Buy	$25.00	N/A
4/1/2017	FBR & Co	Reiterated Rating	Buy		Medium
9/15/2016	Royal Bank of Canada	Set Price Target	Buy	$11.00 -> $10.00	N/A

(Data available from 4/20/2016 forward)

Spectrum Pharmaceuticals (NASDAQ:SPPI) Earnings History and Estimates Chart

Earnings by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ:SPPI) Earnings Estimates

2018 EPS Consensus Estimate: ($1.31)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.35)	($0.31)	($0.33)
Q2 2018	1	($0.32)	($0.32)	($0.32)
Q3 2018	1	($0.33)	($0.33)	($0.33)
Q4 2018	1	($0.33)	($0.33)	($0.33)

Spectrum Pharmaceuticals (NASDAQ SPPI) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
3/6/2018	Q4 2017	($0.25)	($0.29)	$33.18 million	$28.57 million	View	Listen
11/2/2017	Q3 2017	($0.16)	($0.22)	$33.27 million	$36.40 million	View	N/A
8/3/2017	Q2 2017	($0.27)	($0.26)	$30.50 million	$34.30 million	View	Listen
5/2/2017	Q1 2017	($0.20)	($0.18)	$32.23 million	$29.10 million	View	Listen
3/8/2017	Q4 2016	($0.27)	($0.2190)	$31.13 million	$35.24 million	View	Listen
11/14/2016	Q3 2016	($0.30)	($0.22)	$29.53 million	$33.39 million	View	N/A
8/9/2016	Q216	($0.29)	($0.05)	$30.88 million	$33.90 million	View	N/A
5/5/2016	Q1	($0.32)	($0.14)	$28.83 million	$43.90 million	View	N/A
3/9/2016	Q415	($0.18)	($0.06)	$33.87 million	$50.30 million	View	N/A
11/4/2015	Q315	($0.25)	($0.28)	$31.87 million	$28.46 million	View	N/A
8/6/2015	Q215	($0.22)	($0.01)	$34.48 million	$44.98 million	View	N/A
5/7/2015	Q115	($0.06)	($0.07)	$48.00 million	$38.60 million	View	N/A
3/13/2015	Q414	($0.16)	$0.09	$48.50 million	$51.70 million	View	N/A
11/6/2014	Q314	($0.17)	$0.08	$45.00 million	$47.99 million	View	N/A
8/7/2014	Q214	($0.09)	$0.09	$41.50 million	$46.90 million	View	Listen
5/8/2014	Q114	($0.22)	$0.01	$39.49 million	$40.10 million	View	Listen
3/6/2014	Q313	($0.11)	$0.05	$41.96 million	$41.50 million	View	Listen
11/12/2013	Q3	($0.07)	($0.13)	$38.70 million	$42.44 million	View	Listen
8/7/2013	Q2 2013	($0.12)	($0.08)	$33.41 million	$33.23 million	View	N/A
5/9/2013	Q1 2013	($0.32)	($0.06)	$49.88 million	$38.67 million	View	N/A
2/21/2013	Q4 2012	$0.16	$0.18			View	N/A
11/7/2012	Q312	$0.29	$0.42	$68.56 million	$69.00 million	View	N/A
8/8/2012	Q2 2012	$0.31	$0.34			View	N/A
4/26/2012	Q1 2012	$0.28	$0.35			View	N/A
3/1/2012	Q4 2011	$0.28	$0.13			View	N/A
10/28/2011	Q3 2011	$0.09	$0.29			View	N/A
8/4/2011	Q2 2011	$0.13	$0.13			View	N/A
5/4/2011	Q1 2011	$0.01	$0.33			View	N/A
3/10/2011	Q4 2010	($0.04)	$0.14			View	N/A
11/4/2010	Q3 2010	($0.22)	($0.07)			View	N/A
8/9/2010	Q2 2010	($0.15)	($0.20)			View	N/A
5/10/2010	Q1 2010	($0.15)	($0.78)			View	N/A
4/5/2010	Q4 2009	($0.20)	($0.19)			View	N/A
11/12/2009	Q3 2009	($0.20)	($0.17)			View	N/A
8/13/2009	Q2 2009	($0.14)	($0.28)			View	N/A
5/18/2009	Q1 2009	($0.11)	$0.02			View	N/A
3/31/2009	Q4 2008	($0.17)	($0.12)			View	N/A
11/7/2008	Q3 2008	($0.32)	($0.28)			View	N/A
8/12/2008	Q2 2008	($0.34)	$0.34			View	N/A
5/13/2008	Q1 2008	($0.40)	($0.28)			View	N/A
3/14/2008	Q4 2007	($0.38)	($0.41)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Spectrum Pharmaceuticals (NASDAQ:SPPI) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
12/11/2012	special	$0.15		12/18/2012	12/20/2012	12/28/2012

(Data available from 1/1/2013 forward)

Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.33%
Institutional Ownership Percentage: 77.32%

Insider Trading History for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Institutional Ownership by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/18/2018	Rajesh C Md Shrotriya	Director	Sell	90,000	$19.00	$1,710,000.00	200,652
4/17/2018	Joseph W Turgeon	CEO	Sell	11,565	$19.00	$219,735.00	316,509
4/16/2018	Rajesh C Md Shrotriya	Director	Sell	30,000	$18.72	$561,600.00	200,652
4/16/2018	Thomas J Riga	COO	Sell	3,900	$18.60	$72,540.00	254,694
4/13/2018	Rajesh C Md Shrotriya	Director	Sell	30,000	$19.93	$597,900.00	200,652
4/11/2018	Rajesh C Md Shrotriya	Director	Sell	30,000	$20.30	$609,000.00	200,652
4/9/2018	Rajesh C Md Shrotriya	Director	Sell	12,300	$15.01	$184,623.00	200,652
4/6/2018	Rajesh C Md Shrotriya	Director	Sell	3,686	$15.00	$55,290.00	200,652
4/4/2018	Rajesh C Md Shrotriya	Director	Sell	30,000	$15.01	$450,300.00	200,652
4/2/2018	Rajesh C Md Shrotriya	Director	Sell	60,000	$15.90	$954,000.00	200,652
4/2/2018	Thomas J Riga	COO	Sell	1,948	$15.58	$30,349.84	256,452
3/28/2018	Joseph W Turgeon	CEO	Sell	4,810	$16.40	$78,884.00	328,074
3/28/2018	Kurt A Gustafson	CFO	Sell	4,350	$16.35	$71,122.50	187,193
3/28/2018	Rajesh C Md Shrotriya	Director	Sell	90,000	$16.88	$1,519,200.00	200,652
3/26/2018	Kurt A Gustafson	CFO	Sell	1,300	$17.38	$22,594.00	191,543
3/26/2018	Rajesh C Md Shrotriya	Director	Sell	30,000	$17.34	$520,200.00	200,652
3/26/2018	Thomas J Riga	COO	Sell	220	$17.41	$3,830.20	251,476
3/22/2018	Joseph W Turgeon	CEO	Sell	3,100	$18.17	$56,327.00	332,884
3/22/2018	Kurt A Gustafson	CFO	Sell	2,640	$18.13	$47,863.20	192,843
3/21/2018	Stuart Mitchell Krassner	Director	Sell	4,200	$18.64	$78,288.00	83,257
2/5/2013	Anthony E Maida III	Director	Sell	5,000	$12.25	$61,250.00
11/12/2012	Joseph Kenneth Keller	COO	Buy	10,000	$10.95	$109,500.00
11/1/2012	Anthony E Maida III	Director	Sell	5,000	$11.09	$55,450.00
9/4/2012	Anthony E Maida III	Director	Sell	5,000	$12.01	$60,050.00

(Data available from 1/1/2013 forward)

Spectrum Pharmaceuticals (NASDAQ SPPI) News Headlines

Source:

Date	Headline
	Zacks: Analysts Anticipate Spectrum Pharmaceuticals (SPPI) Will Announce Quarterly Sales of $26.10 Million www.americanbankingnews.com - April 20 at 1:06 AM
	Spectrum Pharma (SPPI) Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers www.streetinsider.com - April 19 at 8:13 AM
	Brokerages Anticipate Spectrum Pharmaceuticals (SPPI) to Post -$0.24 EPS www.americanbankingnews.com - April 18 at 11:22 PM
	Spectrum Pharmaceuticals (SPPI) CEO Sells $219,735.00 in Stock www.americanbankingnews.com - April 18 at 7:46 PM
	Spectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 30,000 Shares www.americanbankingnews.com - April 18 at 7:29 PM
	Rajesh C. Md Shrotriya Sells 90,000 Shares of Spectrum Pharmaceuticals (SPPI) Stock www.americanbankingnews.com - April 18 at 7:16 PM
	Spectrum Pharmaceuticals: What To Expect From This Powerful Grower seekingalpha.com - April 18 at 8:15 AM
	Thomas J. Riga Sells 3,900 Shares of Spectrum Pharmaceuticals (SPPI) Stock www.americanbankingnews.com - April 17 at 7:28 PM
	Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American ... www.businesswire.com - April 17 at 5:56 PM
	Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago finance.yahoo.com - April 17 at 5:56 PM
	Spectrum Pharmaceuticals (SPPI) Lowered to "Sell" at Zacks Investment Research www.americanbankingnews.com - April 16 at 1:19 PM
	Spectrum Pharmaceuticals (SPPI) Lowered to "Buy" at BidaskClub www.americanbankingnews.com - April 14 at 9:13 PM
	Spectrum Pharmaceuticals (SPPI) Director Sells $597,900.00 in Stock www.americanbankingnews.com - April 13 at 7:13 PM
	Rajesh C. Md Shrotriya Sells 30,000 Shares of Spectrum Pharmaceuticals (SPPI) Stock www.americanbankingnews.com - April 13 at 7:13 PM
	Wait for a Pullback Before Rolling the Dice on SPPI Stock investorplace.com - April 12 at 9:25 PM
	Form 4 SPECTRUM PHARMACEUTICALS For: Apr 06 Filed by: SHROTRIYA RAJESH C MD www.streetinsider.com - April 12 at 8:33 AM
	Implied Volatility Surging for Spectrum Pharmaceuticals (SPPI) Stock Options finance.yahoo.com - April 12 at 8:33 AM
	Spectrum Pharmaceuticals (SPPI) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow seekingalpha.com - April 12 at 8:33 AM
	Wired News – Spectrum Pharma Reported Update Data from MD Anderson’s Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC Patients finance.yahoo.com - April 12 at 8:33 AM
	Spectrum Pharmaceuticals (SPPI) Upgraded at Zacks Investment Research www.americanbankingnews.com - April 11 at 6:45 PM
	Spectrum Down Following Positive Cancer Drug Test www.baystreet.ca - April 11 at 5:34 PM
	7 Stocks To Watch For April 11, 2018 www.benzinga.com - April 11 at 8:28 AM
	BioSci Rounds Report: Strong Data Catapulted Spectrum While Intercept Is Poised For Growth seekingalpha.com - April 11 at 8:28 AM
	Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data seekingalpha.com - April 11 at 8:28 AM
	Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Tandem Diabetes Care finance.yahoo.com - April 11 at 8:28 AM
	Insider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 12,300 Shares of Stock www.americanbankingnews.com - April 10 at 10:16 PM
	Rajesh C. Md Shrotriya Sells 3,686 Shares of Spectrum Pharmaceuticals (SPPI) Stock www.americanbankingnews.com - April 10 at 10:16 PM
	Spectrum Pharmaceuticals (SPPI) Is Up Sharply On Study Results www.nasdaq.com - April 10 at 5:31 PM
	Spectrum Pharmaceuticals (SPPI) Shares Cross Above 200 DMA www.nasdaq.com - April 10 at 5:31 PM
	Why Spectrum Pharmaceuticals, Inc. Is Soaring Today finance.yahoo.com - April 10 at 5:31 PM
	Why Sprint, Spectrum Pharmaceuticals, and NVIDIA Jumped Today finance.yahoo.com - April 10 at 5:31 PM
	Spectrum Pharmaceuticals (SPPI) PT Raised to $13.00 at Jefferies Group www.americanbankingnews.com - April 8 at 8:05 PM
	Spectrum Pharmaceuticals (SPPI) Lowered to Sell at BidaskClub www.americanbankingnews.com - April 4 at 9:30 AM
	Spectrum Pharmaceuticals Target of Unusually Large Options Trading (SPPI) www.americanbankingnews.com - April 4 at 6:52 AM
	CASI Pharmaceuticals To Present At The H.C. Wainwright Global Life Sciences Conference www.bizjournals.com - April 3 at 8:19 AM
	Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 10th finance.yahoo.com - April 3 at 8:19 AM
	Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Insmed finance.yahoo.com - April 3 at 8:19 AM
	Spectrum Pharmaceuticals (SPPI) Expected to Post Quarterly Sales of $26.10 Million www.americanbankingnews.com - April 3 at 2:08 AM
	ValuEngine Upgrades Spectrum Pharmaceuticals (SPPI) to "Buy" www.americanbankingnews.com - April 3 at 12:00 AM
	Thomas J. Riga Sells 1,948 Shares of Spectrum Pharmaceuticals (SPPI) Stock www.americanbankingnews.com - April 2 at 10:41 PM
	Spectrum Pharmaceuticals (SPPI) Director Sells $954,000.00 in Stock www.americanbankingnews.com - April 2 at 10:21 PM
	Analysts Expect Spectrum Pharmaceuticals (SPPI) Will Announce Earnings of -$0.31 Per Share www.americanbankingnews.com - April 1 at 11:26 PM
	Spectrum Pharmaceuticals (SPPI) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - April 1 at 5:28 PM
	Kurt A. Gustafson Sells 4,350 Shares of Spectrum Pharmaceuticals (SPPI) Stock www.americanbankingnews.com - March 28 at 10:46 PM
	Spectrum Pharmaceuticals (SPPI) CEO Sells $78,884.00 in Stock www.americanbankingnews.com - March 28 at 10:46 PM
	Insider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 30,000 Shares of Stock www.americanbankingnews.com - March 28 at 10:32 PM
	Spectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 90,000 Shares www.americanbankingnews.com - March 28 at 10:31 PM
	Kurt A. Gustafson Sells 1,300 Shares of Spectrum Pharmaceuticals (SPPI) Stock www.americanbankingnews.com - March 27 at 11:14 PM
	Spectrum Pharmaceuticals (SPPI) Stock Rating Lowered by TheStreet www.americanbankingnews.com - March 24 at 12:28 AM
	Spectrum Pharmaceuticals (SPPI) Director Sells $78,288.00 in Stock www.americanbankingnews.com - March 23 at 7:32 PM

Spectrum Pharmaceuticals (NASDAQ:SPPI) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Spectrum Pharmaceuticals (NASDAQ:SPPI) Income Statement, Balance Sheet and Cash Flow Statement

Spectrum Pharmaceuticals (NASDAQ SPPI) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff